Dr. Kurien is a Radiation Oncologist at TBCC, specializing in the treatment of lung cancers, sarcomas and radiotherapy for benign disorders.
Biography
Area of Focus
Summary of Research
- Taggar AS, Graham D, Kurien E, Grafe JL. Volumetric-modulated arc therapy versus intensity-modulated radiotherapy for large volume retroperitoneal sarcomas: A comparative analysis of dosimetric and treatment delivery parameters. J Appl Clin Med Phys 2018 Jan;19(1)276-81.
- Swaminath A, Wierzbicki M, Parpia S, Wright JR, Tsakiridis TK, Okawara GS, Kundar V, Bujold A, Ahmed N, Hirmiz K, Kurien E, Filion E, Gabos Z, Faria S, Louie AV, Owen T, Wai E, Ramchandar K, Chan EK, Julian J, Cline K, Whelan TJ. Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Fractionated Radiotherapy for Stage I, Medically Inoperable Non-Small Cell Lung Cancer – Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial. Clin Lung Cancer 2017 Mar;18(2) 250-4.
- Cheung P, Faria S, Ahmed S, Chabot P, Greenland J, Kurien E, Mohamed I, Wright J, Hollenhorst H, de Metz C, Campbell H, Vu T, Karvat A, Wai E, Ung Y, Goss G, O’Brien P, Shepherd F, Ding K, O’Callaghan C. Phase II Study of Accelerated Hypofractionated 3-Dimensional Conformal Radiotherapy For Stage T1-3 N0 M0 Non-Small Cell Lung Cancer: NCIC CTG BR.25. J Natl Cancer Inst 106(8). Jul 29, 2014.
Area Of Focus
Summary Of Research
- Taggar AS, Graham D, Kurien E, Grafe JL. Volumetric-modulated arc therapy versus intensity-modulated radiotherapy for large volume retroperitoneal sarcomas: A comparative analysis of dosimetric and treatment delivery parameters. J Appl Clin Med Phys 2018 Jan;19(1)276-81.
- Swaminath A, Wierzbicki M, Parpia S, Wright JR, Tsakiridis TK, Okawara GS, Kundar V, Bujold A, Ahmed N, Hirmiz K, Kurien E, Filion E, Gabos Z, Faria S, Louie AV, Owen T, Wai E, Ramchandar K, Chan EK, Julian J, Cline K, Whelan TJ. Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Fractionated Radiotherapy for Stage I, Medically Inoperable Non-Small Cell Lung Cancer – Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial. Clin Lung Cancer 2017 Mar;18(2) 250-4.
- Cheung P, Faria S, Ahmed S, Chabot P, Greenland J, Kurien E, Mohamed I, Wright J, Hollenhorst H, de Metz C, Campbell H, Vu T, Karvat A, Wai E, Ung Y, Goss G, O’Brien P, Shepherd F, Ding K, O’Callaghan C. Phase II Study of Accelerated Hypofractionated 3-Dimensional Conformal Radiotherapy For Stage T1-3 N0 M0 Non-Small Cell Lung Cancer: NCIC CTG BR.25. J Natl Cancer Inst 106(8). Jul 29, 2014.